#AstellasPharma

The Phase III PASHA trial of XOSPATA™ reported no statistically significant difference in the primary endpoint of overall survival, with minimal impact expected on full-year financial results.

Astellas Pharma is promoting company-wide initiatives and setting indicators to improve sustainability. The social impact for FY2024 is reported as Product Impact of USD 27,861 million, Human Capital Impact of USD 528.5 million, and Environmental Impact of -USD 32.7 million.

Astellas Pharma reached a settlement with Lupin and Zydus in the Myrbetriq® patent infringement lawsuit, receiving a total of USD 60 million in settlement payments and USD 150 million in upfront license fees.

Astellas Pharma announced that the combination therapy of PADCEV (Enfortumab Vedotin) and Pembrolizumab improved event-free survival and overall survival in cisplatin-eligible muscle-invasive bladder cancer in the Phase III EV-304 trial.